Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Acquisition of TeneoTwo completed

11 August 2022 07:00 BST Acquisition of TeneoTwo for its clinical-stage T-cell engager completed AstraZeneca has completed the acquisition of TeneoTwo, Inc . (TeneoTwo)[i], including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.[1] AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. Financial considerations

Flexion Mobile signs agreement with Clicktouch to launch hit game in Japan

LONDON, 11th of August 2022 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company has signed an agreement with Clicktouch Co., Ltd. to publish Call Me Emperor (アイアム皇帝) on the alternative app stores.  Flexion will distribute the hit game on Amazon Japan in September 2022. Call Me Emperor already earns US$6 million in monthly gross revenue on Google Play according to the developer’s data.  Flexion’s distribution services will add revenue and new players from the alternative app stores with little upfront cost or work being required of the developer. Flexion is adding

Anora invests in ISH, the award-winning Danish scale-up company in non-alcoholic beverages

Anora has made an investment of EUR 5 million in ISH, the Danish scale-up company in non-alcoholic beverages, making Anora a minority shareholder in the company. The investment will enable ISH to further accelerate its international growth. Anora will be distributing ISH’s alcohol-free products in Norway, Sweden, and Finland. The agreement between Anora and ISH was completed on 20 July 2022.ISH is a global leader in non-alcoholic (NA) markets with a broad portfolio of award-winning non-alcoholic spirits, wines and ready-to-drink beverages. The company was founded in 2018 on the premise that

UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis

· Topline results expected in first half of 2023 · Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD)   Hellerup, Denmark, 11 August 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announces that it has completed enrollment of the last patient in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of

Successfully focusing on core business

STOCKHOLM – 12 of August 2022 – ContextVision, a medical technology software company specializing in image processing, delivered the Company’s best ever second quarter revenue numbers and a significant EBITDA increase. Sales in the second quarter reached MSEK 32,5 (24.4), an 19% increase compared with the previous quarter, and an increase of 26% versus last year’s corresponding quarter when adjusted for currency exchange effects. EBITDA reached MSEK 15,5 (11,4). The revenue increase is coming from new strategic contracts as well as expanding on current contracts with existing

Acroud publishes interim report Apr-Jun 2022: Continued strong organic growth with refinancing secured

Second Quarter 2022   · Revenue amounted to EUR 7 200 (6 200) thousand, corresponding to a growth of 16% and an organic growth of 15%.    · EBITDA amounted to EUR 1 802 (1 159) thousand, increasing by 55% year-on-year. Adjusted EBITDA (before items affecting comparability) was EUR 1 802 (1 500) thousand, increasing by 20% year-on-year.    · Profit after tax was EUR 1 248 (-267) thousand. Adjusted profit after tax (before items affecting comparability and currency effects) was EUR 588 (292) thousand.   · Earnings per share after dilution amounted to EUR 0.010 (

Relais Group Plc Half-year financial report January–June 2022 (unaudited)

Relais Group PlcCompany release 11 August 2022, 9:00 a.m. EEST This release is a summary of Relais Group's Half-year financial report January–June 2022. The full release is attached to this company release and is available on our website at https://relais.fi/en/investors/. APRIL–JUNE 2022 IN BRIEF · Net sales totaled EUR 58.6 million (April – June 2021: 52.2), +12.2% change · EBITDA was EUR 4.2 (5.4) million, 7.2% (10.3%) of net sales, -21.3% change · EBITA was EUR 3.7 (4.8) million, 6.4% (9.2%) of net sales, -22.6% change · EBIT was EUR -0.0 (1,5) million, -0.1% (2.9%)

Oncopeptides publishes Q2 report 2022

STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the second quarter 2022.“CHMPs recommendation to grant Pepaxti a full marketing authorization approval in EU is foundational for Oncopeptides says Jakob Lindberg, CEO of Oncopeptides. “This is excellent news for patients, shareholders, and for the future development of Oncopeptides.” Financial overview April-June · Net sales amounted to SEK 8.8 M (66.4) ·

FlexQubes report for the second quarter 2022

SECOND QUARTER 2022 · Order intake increased by 69.3 percent to 54.9 MSEK (32.4). Adjusted for foreign exchange rate effects between the comparison periods, order intake increased by 47.2 percent. · Net sales increased by 111.4 percent to 56.1 MSEK (26.5). Adjusted for foreign exchange rate effects between the comparison periods, net sales increased by 89.3 percent. · Operating profit before depreciation (EBITDA) amounted to 1.5 MSEK (-1.6) and operating profit before financial items (EBIT) amounted to 0.3 MSEK (-2.7). · Profit before tax amounted to 0.2 MSEK (-2.8). ·

Transcom Holding AB (publ): Invitation to Transcom second quarter 2022 results presentation webcast

Transcom are pleased to invite you to their Q2 2022 financial update webcast on Thursday, August 25, at 9:00 am CET, following the release of Q2 2022 results at 8:00 am CET. The Q2 report and presentation will be available on https://www.transcom.com/global/about-us/investor-relations. Representing Transcom Jonas Dahlberg, President & CEOSnejana Koleva, CFO Presentation details Date/Time: Thursday, August 25, at 9:00 am CETOnline Registration link: https://app.livestorm.co/transcom-holding/transcom-holding-ab-q2-2022-results-presentation   Important note: Please register

Olvi Group’s half-year report 1 January to 30 June 2022 (6 months)

OLVI PLC                  Half-year report 11 August 2022 at 9 am Olvi Group’s half-year report 1 January to 30 June 2022 (6 months) Half-year report in brief Olvi Group’s sales volume and net sales developed strongly during the second quarter, in line with the favourable trend that prevailed in the first quarter. The Group’s operating profit decreased during the review period, but the previous year’s level was achieved in the second quarter despite significant and rapid cost increases. The impact of higher costs has been successfully reduced through price increases in all markets.

H+H International A/S to present H1 2022 Interim Financial Report

H+H International A/S expects to release its interim financial report for the first six months of 2022 (“H1 2022”) on Thursday 18 August 2022. In connection with the release of the H1 2022 Interim Financial Report, a conference call for investors and analysts is scheduled for Friday 19 August 2022 at 10:00 a.m. CEST. On the call, CEO Michael T. Andersen and CFO Peter Klovgaard-Jørgensen will present the interim financial report. The presentation will be followed by a Q&A session. Investors and analysts are invited to participate via phone (PIN code: 275042): DK: +45 78768490UK:

Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases

AQILION AB (publ) announces today that the Phase 1 clinical safety study on the drug candidate AQ280 on healthy volunteers has started. The substance AQ280, part of the company’s Regulus development program, is a super selective JAK1 small molecule inhibitor that is under development for indications within chronic inflammatory diseases. Aqilion has thus reached a very important milestone as the company has managed to take the big step from preclinical phase to clinical Phase 1.  The Phase 1 clinical trial, ARIA-1, will include 64 healthy volunteers. The purpose of the study is to

Nixu Corporation’s Half-Year Financial Report 2022: Positive business development continued with 7% growth

Nixu Corporation, Stock Exchange Release on August 11, 2022 at 8:30 a.m. EESTThis release is a summary of the Nixu Corporation’s January 1 – June 30, 2022 Half-Year Financial report. The complete report is attached to this release as a pdf-file. It is also available on the company website at https://www.nixu.com/H12022. Highlights for January–June 2022 • Revenue: EUR 28,580 thousand (26,720), change 7%. • EBITDA: EUR 377 thousand (805), share of revenue: 1% (3%). • Adjusted EBITDA: EUR 352 thousand (1,198), share of revenue: 1% (5%). • EBIT: EUR -553 thousand (-154), share of

Anders Fogelberg intends to quit as CEO at FlexQube and take a new role in the company

After nine years as CEO and as a natural step in the company's next phase to become a leading global robotics and automation company, Anders Fogelberg has decided, in agreement with the Board to leave the role as CEO and instead further strengthen FlexQube's continued expansion, with a focus on global strategy, sales and business development. Anders will remain as CEO until a new CEO has been recruited and will then remain in the company and continue the work of driving sales development and strategy of the company's products and customers on the international market. Recruitment of a

Teleste corporation half year financial report 1 january to 30 june 2022: Strong demand continued, but the result declined due to component supply shortages

TELESTE CORPORATION    HALF YEAR FINANCIAL REPORT     11 AUGUST 2022 AT 8:30 EET   TELESTE CORPORATION HALF YEAR FINANCIAL REPORT 1 JANUARY TO 30 JUNE 2022     STRONG DEMAND CONTINUED, BUT THE RESULT DECLINED DUE TO COMPONENT SUPPLY SHORTAGES     April-June 2022   - Net sales amounted to EUR 38.4 (35.8) million, an increase of 7.2% - The adjusted operating result was EUR 0.3 (1.1) million, a decrease of 70.2% - The operating result was EUR 0.2 (1.1) million, a decrease of 83.0% - Adjusted earnings per share were EUR -0.07 (0.04), a decrease of 261.5%

Significantly improved results and good revenue growth

Readly International AB (publ) presents a second quarter with significantly improved results and good revenue growth. Gross profit increased by 30.8 percent to SEK 48.8 (37.3) million, corresponding to a gross margin of 33.8 percent. Adjusted for items affecting comparability of SEK -2.5 million, the EBITDA margin improved to -13.7 (-46.5) percent and the operating margin to -17.8 (-49.0) percent in the quarter. Gross contribution improved to SEK 29.0 (-11.5) million, corresponding to a positive gross contribution margin of 20.1 (-10.4) percent. The number of fully paying subscribers

SMART WIRES TECHNOLOGY LTD, Q2 2022 INTERIM REPORT

“Revenue in the second quarter of $8.2M was in-line with our previously communicated guidance that more than 70% of revenue will be in the second half of the year as supply chain disruption continued to impact production timing and associated deliveries. After the end of the quarter, we updated the market on the company’s outlook for the rest of 2022. We lowered the revenue outlook to $55M to $60M compared to the previously stated $65M to $70M due to the impact of continued supply chain disruption on our production volume and technology deployment. Cash at the end of the quarter was

A good result characterised by growth, increased income and reversed impairment provisions

SpareBank 1 SR-Bank ASA (SRBNK) achieved a pre-tax profit of NOK 1,021 million in the second quarter of 2022, compared with NOK 959 million for the same period last year. The return on equity after tax for the quarter was 12.0%. High lending growth, increased net interest income and reversed impairment provisions lead to the good result. The group had a total lending growth of 7.6% in the past 12 months. There was significant growth in the retail market (6.1%), in the corporate market (10.7%) and SME & agriculture (8.5%), where positive development in the business sector contributed to

Fazer Leipurit reduces bread waste and encourages a change of mindset in the whole food chain

Fazer's in-store bakery business has taken a huge leap in growth, and the number of bakeries throughout Finland has tripled to 120 in just five years. Now the company is seeking to reduce food waste at its in-store bakeries by optimising bakery volumes and assortment to an even greater extent. Reducing food waste is one of the most efficient ways of mitigating the environmental effects of food. Fazer Leipurit has set a goal of having all the bread baked in artisan bakeries sold by the end of each day.A critical review of our ways of working encourages the whole food chain to adopt a new

Solteq Plc: Change in the Audit Committee of the Board of Directors

Stock Exchange BulletinAugust 11, 2022, at 8:15 a.m. Solteq Plc’s Audit Committee of the Board of Directors has been reorganized by the appointment of Mika Sutinen as a member of the committee. Going forward, the Audit Committee is organized as following: •    Mika Sutinen, Chairman of the Audit Committee•    Katarina Segerståhl, member of the Audit Committee•    Markku Pietilä, member of the Audit Committee The Audit Committee consists of one member independent of the company and two members independent of the company and its significant shareholders.  The change in the

Nel ASA: Will build a second production line at Herøya

(Oslo, 11 August 2022) Nel ASA (Nel, OSE:NEL) Nel has decided to build a new fully automated production line at Herøya in Norway, doubling its capacity for production of alkaline electrolyser stacks to ~1 GW. “The expansion means that Nel is strengthening its position as a global frontrunner for development and industrialization of green hydrogen technology and provides Norway with a great opportunity to take on the role as the leading exporter of electrolyser equipment to a rapidly growing market,” says Nel’s CEO Håkon Volldal.   The investment decision was made only weeks after the

Solteq Plc Half-Year Report January 1 – June 30, 2022

Stock Exchange BulletinAugust 11, 2022 at 8.00 am Challenges in the Utilities Business Weakened the Profitability of SolteqApril–June  · Revenue totaled EUR 17.9 million (18.5) and decreased by 3.0 percent · EBITDA was EUR 1.8 million (3.7) and EBITDA percent was 9.9 (20.2) · Operating profit was EUR 0.4 million (2.4) and operating profit percent was 2.3 (13.2) · Earnings per share was EUR 0.00 (0.08) January–June  · Revenue totaled EUR 37.2 million (35.9) and increased by 3.6 percent · EBITDA was EUR 4.5 million (7.2) and EBITDA percent was 12.1 (20.1)

Interim Report January – June 2022

“The second quarter remained busy as the company and its employees continued to adapt to the war in Ukraine and the difficult global economic environment. We have made great progress in the relocation of employees and the pace of relocation has increased month by month in the second quarter,” said Vlad Suglobov, CEO of G5 Entertainment. “As we flagged previously, we boosted our investment in user acquisition (UA) to stimulate faster revenue growth of Sherlock. The company’s UA expenses as a percent of revenue rose to 35 percent as we targeted growth in Sherlock's audience. The boost for

There are no items matching the current filter
There are no more items matching the current filter
Back to top